Evidence supporting the use of: Ornithine l-aspartic acid
For the body system: Hepatic System

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Ornithine l-aspartic acid (LOLA) is primarily used to support the hepatic system, especially in the management of hepatic encephalopathy (HE), a neuropsychiatric complication of liver dysfunction. The rationale stems from LOLA’s ability to facilitate ammonia detoxification, a key factor in HE pathogenesis. LOLA acts as a substrate in the urea cycle (ornithine) and in the synthesis of glutamine (aspartic acid), both of which help reduce blood ammonia levels. Several randomized controlled trials and meta-analyses have demonstrated that LOLA can effectively lower ammonia concentrations and improve mental status in patients with mild to moderate HE. For example, a 2013 meta-analysis in Alimentary Pharmacology & Therapeutics found that both intravenous and oral LOLA significantly improved clinical outcomes in HE compared to placebo. Furthermore, guidelines from professional associations such as the European Association for the Study of the Liver (EASL) mention LOLA as an option for HE management. However, while the evidence is generally positive, it is not as robust as for some other HE therapies (e.g., lactulose), and some studies show variable results. There is less evidence for LOLA’s use in broader hepatic support outside of HE. In summary, scientific evidence supports the use of ornithine l-aspartic acid for specific hepatic conditions, particularly hepatic encephalopathy, with a moderate level of clinical validation.

More about Ornithine l-aspartic acid
More about Hepatic System

Other body systems supported by Ornithine l-aspartic acid

Digestive System
Hepatic System
Liver

Products containing Ornithine l-aspartic acid

We currently have no products on Vitabase that contain this ingredient.